Valeant Completes $1.5 Billion Notes Offering
Date: 03/08/11
Cahill represented the initial purchasers in a Rule 144A/Reg S Offering of $950 million of 6.500% Senior Notes due 2016 and $550 million of 7.250% Senior Notes due 2022 by Valeant Pharmaceuticals International. Valeant intends to use the net proceeds from the offering to prepay amounts outstanding under its term loan credit facility, fund the repurchase of common shares and the redemption of Valeant's 4.0% convertible subordinated notes due 2013 and for general corporate purposes.